New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT05586841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested two oral drugs, dalpiciclib and chidamide, in 22 people with HR+/HER2- advanced breast cancer whose disease had worsened after CDK4/6 inhibitor therapy. The main goal was to find the safest dose. Researchers also looked at how well the combination shrank tumors and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dalpiciclib and chidamide (oral drugs)
What this could lead to
If successful, this could provide a new treatment option for people with advanced breast cancer whose current therapy has stopped working.
What could go wrong
This is a very early, small phase 1b study with only 22 participants, so results may not apply broadly. The main goal is to find a safe dose, not yet to prove effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100071, China